BioGaia AB (publ) (BIOG-B.ST)
SEK 110.5
(0.82%)
SEK 110.5
(0.82%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.29 Billion SEK | 17.44% |
| 2022 | 1.1 Billion SEK | 40.61% |
| 2021 | 785.11 Million SEK | 5.09% |
| 2020 | 747.07 Million SEK | -2.77% |
| 2019 | 768.34 Million SEK | 3.57% |
| 2018 | 741.87 Million SEK | 20.63% |
| 2017 | 615 Million SEK | 15.02% |
| 2016 | 534.69 Million SEK | 10.65% |
| 2015 | 483.24 Million SEK | 0.3% |
| 2014 | 481.8 Million SEK | 52.53% |
| 2013 | 315.87 Million SEK | -51.05% |
| 2012 | 645.25 Million SEK | 104.85% |
| 2011 | 314.99 Million SEK | 33.45% |
| 2010 | 236.03 Million SEK | 16.01% |
| 2009 | 203.46 Million SEK | 40.13% |
| 2008 | 145.19 Million SEK | 36.23% |
| 2007 | 106.58 Million SEK | 22.8% |
| 2006 | 86.79 Million SEK | 45.61% |
| 2005 | 59.6 Million SEK | 47.4% |
| 2004 | 40.43 Million SEK | 13.43% |
| 2003 | 35.65 Million SEK | -17.3% |
| 2002 | 43.1 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 369.8 Million SEK | 24.19% |
| 2024 Q2 | 384.12 Million SEK | 3.87% |
| 2024 Q3 | 303.97 Million SEK | -20.87% |
| 2023 FY | 1.29 Billion SEK | 17.44% |
| 2023 Q2 | 315.21 Million SEK | -13.83% |
| 2023 Q1 | 365.82 Million SEK | 33.37% |
| 2023 Q4 | 297.77 Million SEK | -6.27% |
| 2023 Q3 | 317.69 Million SEK | 0.79% |
| 2022 Q2 | 288.08 Million SEK | 1.49% |
| 2022 Q3 | 257.73 Million SEK | -10.54% |
| 2022 FY | 1.1 Billion SEK | 40.61% |
| 2022 Q1 | 283.85 Million SEK | 37.69% |
| 2022 Q4 | 274.28 Million SEK | 6.42% |
| 2021 Q4 | 206.16 Million SEK | 18.59% |
| 2021 FY | 785.11 Million SEK | 5.09% |
| 2021 Q1 | 201.97 Million SEK | 7.66% |
| 2021 Q2 | 203.13 Million SEK | 0.57% |
| 2021 Q3 | 173.84 Million SEK | -14.42% |
| 2020 Q4 | 187.61 Million SEK | 42.17% |
| 2020 Q1 | 182.8 Million SEK | -11.95% |
| 2020 Q2 | 244.69 Million SEK | 33.85% |
| 2020 Q3 | 131.96 Million SEK | -46.07% |
| 2020 FY | 747.07 Million SEK | -2.77% |
| 2019 Q3 | 167.14 Million SEK | -24.82% |
| 2019 FY | 768.34 Million SEK | 3.57% |
| 2019 Q1 | 171.25 Million SEK | -18.32% |
| 2019 Q4 | 207.61 Million SEK | 24.21% |
| 2019 Q2 | 222.33 Million SEK | 29.82% |
| 2018 Q2 | 200.87 Million SEK | 28.24% |
| 2018 Q4 | 209.67 Million SEK | 20.04% |
| 2018 FY | 741.87 Million SEK | 20.63% |
| 2018 Q1 | 156.64 Million SEK | -7.94% |
| 2018 Q3 | 174.67 Million SEK | -13.05% |
| 2017 Q1 | 141.13 Million SEK | 1.72% |
| 2017 Q4 | 170.14 Million SEK | 15.22% |
| 2017 Q3 | 147.67 Million SEK | -5.36% |
| 2017 FY | 615 Million SEK | 15.02% |
| 2017 Q2 | 156.04 Million SEK | 10.57% |
| 2016 Q4 | 138.75 Million SEK | 10.08% |
| 2016 Q2 | 136.04 Million SEK | 1.64% |
| 2016 Q1 | 133.85 Million SEK | 28.22% |
| 2016 FY | 534.69 Million SEK | 10.65% |
| 2016 Q3 | 126.04 Million SEK | -7.35% |
| 2015 Q1 | 138.84 Million SEK | 14.4% |
| 2015 FY | 483.24 Million SEK | 0.3% |
| 2015 Q4 | 104.39 Million SEK | -1.5% |
| 2015 Q3 | 105.98 Million SEK | -20.92% |
| 2015 Q2 | 134.02 Million SEK | -3.48% |
| 2014 Q2 | 92.37 Million SEK | -51.02% |
| 2014 Q3 | 79.43 Million SEK | -14.01% |
| 2014 Q4 | 121.37 Million SEK | 52.8% |
| 2014 Q1 | 188.61 Million SEK | 109.06% |
| 2014 FY | 481.8 Million SEK | 52.53% |
| 2013 FY | 315.87 Million SEK | -51.05% |
| 2013 Q2 | 85.34 Million SEK | 9.22% |
| 2013 Q4 | 90.22 Million SEK | 45.12% |
| 2013 Q3 | 62.16 Million SEK | -27.15% |
| 2013 Q1 | 78.14 Million SEK | 7.93% |
| 2012 Q4 | 72.4 Million SEK | 15.27% |
| 2012 Q3 | 62.81 Million SEK | -17.07% |
| 2012 Q2 | 75.74 Million SEK | -3.25% |
| 2012 Q1 | 78.28 Million SEK | -4.98% |
| 2012 FY | 645.25 Million SEK | 104.85% |
| 2011 Q4 | 82.39 Million SEK | 12.71% |
| 2011 Q1 | 69.85 Million SEK | 11.31% |
| 2011 Q2 | 89.63 Million SEK | 28.31% |
| 2011 Q3 | 73.1 Million SEK | -18.44% |
| 2011 FY | 314.99 Million SEK | 33.45% |
| 2010 Q1 | 58.56 Million SEK | 11.99% |
| 2010 Q3 | 48.85 Million SEK | -25.81% |
| 2010 FY | 236.03 Million SEK | 16.01% |
| 2010 Q2 | 65.85 Million SEK | 12.44% |
| 2010 Q4 | 62.75 Million SEK | 28.45% |
| 2009 Q2 | 60.2 Million SEK | 15.27% |
| 2009 Q1 | 52.23 Million SEK | 0.0% |
| 2009 FY | 203.46 Million SEK | 40.13% |
| 2009 Q4 | 52.29 Million SEK | 35.06% |
| 2009 Q3 | 38.72 Million SEK | -35.68% |
| 2008 Q2 | 36.36 Million SEK | 0.0% |
| 2008 FY | 145.19 Million SEK | 36.23% |
| 2007 FY | 106.58 Million SEK | 22.8% |
| 2006 FY | 86.79 Million SEK | 45.61% |
| 2005 FY | 59.6 Million SEK | 47.4% |
| 2004 FY | 40.43 Million SEK | 13.43% |
| 2003 FY | 35.65 Million SEK | -17.3% |
| 2002 FY | 43.1 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| Enzymatica AB (publ) | 50.9 Million SEK | -2446.963% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -95371.723% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | -4320.861% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | -3420.34% |
| ODI Pharma AB | 22.44 Million SEK | -5675.822% |
| Orexo AB (publ) | 638.8 Million SEK | -102.96% |
| Probi AB (publ) | 627.68 Million SEK | -106.553% |
| Swedencare AB (publ) | 2.32 Billion SEK | 44.227% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 94.14% |
| Toleranzia AB | 50.92 Million SEK | -2446.163% |
| Vivesto AB | 1.01 Million SEK | -127634.581% |